NHNao Hasuzawa

Nao Hasuzawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nao Hasuzawa has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Masatoshi Nomura

    Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine

    5 shared publications
  • Yoshinori Moriyama

    Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan

    5 shared publications
  • Ayako Nagayama

    Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan

    4 shared publications
  • Kenji Ashida

    Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan

    4 shared publications
  • Lixiang Wang

    Department of Medical Biochemistry, Kurume University School of Medicine, Kurume, Japan

    4 shared publications
  • Masaharu Kabashima

    Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan

    3 shared publications

Latest Publications

  • Vesicular nucleotide transporter (VNUT)-dependent ATP secretion by hepatic stellate cells promotes liver fibrosis

    by Masaharu Kabashima, Nao Hasuzawa, Lixiang Wang, Junjiro Rikitake, Seiji Nomura, Tomohiro Niimoto, Rie Tokubuchi, Sawako Moriyama, Mizuki Gobaru, Yukihiro Inoguchi, et al.


  • Open Access

    Development of a questionnaire-based Dietary Inflammatory Index assessment for clinical implementation

    by Mamiko Yano, Nao Hasuzawa, Natsumi Maruyama, Lixiang Wang, Mizuki Gobaru, Ayako Nagayama, Kenji Ashida, Hitoshi Obara, Kenta Murotani, Yoshinori Moriyama, et al.

    The rising incidence of chronic metabolic diseases places a significant economic burden on healthcare systems. Although the efficacy of lifestyle interventions has been reported, clinical nutrition typically emphasizes total energy and macronutrient intake without consensus on ideal dietary patterns. The Dietary Inflammatory Index (DII) assesses the inflammatory potential of diets and has been linked to diseases like cardiovascular disease, cancer, and type 2 diabetes. However, DII use in clinical practice is limited by its complexity. In this study, we developed a method to calculate DII scores using a clinically available food frequency questionnaire (FFQ). Thirty healthy volunteers provided 3-day dietary records (DR) and completed the FFQ. Dietitians calculated the intake of 29 nutrients from the DR. A created table of nutrient content per FFQ item enabled nutrient intake and DII score calculation from the FFQ. Statistical analysis showed significant correlations between 27 of 29 nutrient intakes and DII scores from the DR and FFQ. Regression equations were developed to predict actual nutrient intakes from the FFQ. The estimated DII (eDII) calculated using the equations correlated strongly with the DR-derived DII (r = 0.716, p < 0.0001). With low bias and variance, our method supports individualized and inflammation-targeted dietary interventions.

  • Open Access

    Sodium-glucose cotransporter 2 inhibitors—but not insulin—enhance renal branched-chain amino acid catabolism

    by Moeko Sakamoto, Nao Hasuzawa, Lixiang Wang, Kyoko Tashiro, Miyuki Kitamura, Shimpei Iwata, Nobuhiko Wada, Seiji Nomura, Sawako Moriyama, Mizuki Gobaru, et al.

    Aims/hypothesis: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) confer cardio-renal protection, and recent work implicates enhanced branched-chain amino acid (BCAA) catabolism as a potential mechanism in the heart. Whether SGLT2i also promotes renal BCAA catabolism is largely unknown. We hypothesized that SGLT2i enhances renal BCAA catabolism independently of glycemic effects. Methods: We conducted a prospective, single-center, open-label, nonrandomized, controlled clinical study in patients with type 2 diabetes stably treated with insulin, who were assigned to dapagliflozin (5 mg/day with dose-reduced insulin; n=8/9 completed) or insulin dose-up (n=5/8 completed). At 12 weeks, changes in urinary and plasma metabolites and short-chain acylcarnitines related to BCAA catabolism were quantified. To explore mechanisms, 10-week-old db/db mice received luseogliflozin (10 mg/kg/day, p.o.) or insulin glargine (10 U/day, s.c.) for 4 weeks; renal histology, mRNA and protein expression of key enzymes involved in BCAA catabolism, including branched-chain aminotransferase 2 (BCAT2), branched-chain ketoacid dehydrogenase (BCKDH), and BCKD kinase (BCKDK), were assessed. Results: Dapagliflozin treatment induced greater increases in urinary excretion of three BCAA-derived metabolites—3-hydroxypropionic acid, C5-OH carnitine, and 3-hydroxybutyric acid—compared with insulin at comparable glycemic levels. In contrast, C4 carnitine (an earlier metabolite in valine catabolism) rose more with insulin. No corresponding between-group differences were detected in plasma metabolites. In db/db mice, luseogliflozin attenuated glomerular mesangial expansion and tubular epithelial atrophy, and reduced Col1a1 mRNA and TGF-β1 protein, compared with glargine at comparable glycemic levels. Luseogliflozin decreased the phosphorylated (inactive) form of the BCKDH E1α subunit (p-BCKDHA/BCKDHA) and lowered BCKDK protein. mRNA expression of amino acid transporters and BCAT2 expression was unchanged. Conclusions/interpretation: Across complementary human and mouse studies, SGLT2 inhibition was suggested to enhance renal BCAA catabolism compared with insulin at comparable glycemic levels. In humans, increases in urinary BCAA-derived downstream metabolites without corresponding changes in plasma support a kidney-localized metabolic effect. In mice, SGLT2 inhibitor improved renal histopathology, and reduced phosphorylation-mediated inactivation of BCKDH. These findings provide mechanistic, translational evidence that SGLT2i modulate BCAA flux independently of glucose lowering, suggesting BCAA catabolism as a therapeutic axis in diabetic kidney disease. Clinical trial registration: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000052955 , identifier UMIN000052955.


  • Open Access

    Impact of Drp1 Loss on Organelle Interaction, Metabolism, and Inflammation in Mouse Liver

    by Lixiang Wang, Seiji Nomura, Nao Hasuzawa, Sadaki Yokota, Ayako Nagayama, Kenji Ashida, Junjiro Rikitake, Yoshinori Moriyama, Masatoshi Nomura, Ken Yamamoto

    Dynamin-related protein 1 (Drp1) is a crucial player in mitochondrial fission and liver function. The interactions between mitochondria, endoplasmic reticulum (ER), and lipid droplets (LDs) are fundamental for lipid metabolism. This study utilized liver-specific Drp1 knockout (Drp1LiKO) mice to investigate the effects of Drp1 deficiency on organelle interactions, metabolism, and inflammation. Our analysis revealed disrupted interactions between mitochondria and LDs, as well as altered interactions among ER, mitochondria, and LDs in Drp1LiKO mice. Through mass spectrometry and microarray analysis, we identified changes in lipid profiles and perturbed expression of lipid metabolism genes in the livers of Drp1LiKO mice. Further in vitro experiments using primary hepatocytes from Drp1LiKO mice confirmed disturbances in lipid metabolism and increased inflammation. These findings highlight the critical involvement of Drp1 in regulating organelle interactions for efficient lipid metabolism and overall liver health. Targeting Drp1-mediated organelle interactions may offer potential for developing therapies for liver diseases associated with disrupted lipid metabolism.


  • VNUT Is a Therapeutic Target for Type 2 Diabetes and NASH

    by Nao Hasuzawa, Keita Tatsushima, Rie Tokubuchi, Masaharu Kabashima, Masatoshi Nomura

    ATP, used in cells as an energy currency, also acts as an extracellular signaling molecule. Studies of purinergic receptor subtypes have revealed that purinergic chemical transmission plays important roles in various cell types. The vesicular nucleotide transporter (VNUT), the ninth transporter in the SLC17 organic anion transporter family, is essential for vesicular ATP storage and its subsequent release. The VNUT is localized on the membrane of secretory vesicles and actively transports ATP into vesicles using an electrochemical gradient of protons supplied by vacuolar proton ATPase (V-ATPase) as a driving force. ATP acts as a damage-associated molecular pattern (DAMPs), contributing to the persistence of chronic inflammation. Chronic inflammation induces systemic insulin resistance, which is the underlying pathology of type 2 diabetes and non-alcoholic fatty liver disease (NAFLD), ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). We previously demonstrated that ATP transported in insulin granules via the VNUT negatively regulates insulin secretion. We also found that hepatocytes release ATP in a VNUT-dependent manner, which elicits hepatic insulin resistance and inflammation. VNUT-knockout mice exhibited improved glucose tolerance and were resistant to the development of high fat diet-induced NAFLD. In this article, we summarize recent advances in our understanding of the mechanism of the VNUT, the development of inhibitors, and its pathological involvement in type 2 diabetes and NAFLD. The pharmacological inhibition of the VNUT may represent a potential therapeutic approach for the treatment of metabolic diseases.


  • Open Access

    Clodronate, an inhibitor of the vesicular nucleotide transporter, ameliorates steatohepatitis and acute liver injury

    by Nao Hasuzawa, Keita Tatsushima, Lixiang Wang, Masaharu Kabashima, Rie Tokubuchi, Ayako Nagayama, Kenji Ashida, Yoshihiro Ogawa, Yoshinori Moriyama, Masatoshi Nomura

    The vesicular nucleotide transporter (VNUT) is responsible for the vesicular storage and release of ATP from various ATP-secreting cells, and it plays an essential role in purinergic signaling. Although extracellular ATP and its degradation products are known to mediate various inflammatory responses via purinoceptors, whether vesicular ATP release affects steatohepatitis and acute liver injury is far less understood. In the present study, we investigated the effects of clodronate, a potent and selective VNUT inhibitor, on acute and chronic liver inflammation in mice. In a model of methionine/choline-deficient diet-induced non-alcoholic steatohepatitis (NASH), the administration of clodronate reduced hepatic inflammation, fibrosis, and triglyceride accumulation. Clodronate also protected mice against high-fat/high-cholesterol diet-induced steatohepatitis. Moreover, prophylactic administration of clodronate prevented d-galactosamine and lipopolysaccharide-induced acute liver injury by reducing inflammatory cytokines and hepatocellular apoptosis. In vitro, clodronate inhibited glucose-induced vesicular ATP release mediated by VNUT and reduced the intracellular level and secretion of triglycerides in isolated hepatocytes. These results suggest that VNUT-dependent vesicular ATP release plays a crucial role in the recruitment of immune cells, cytokine production, and the aggravation of steatosis in the liver. Pharmacological inhibition of VNUT may provide therapeutic benefits in liver inflammatory disorders, including NASH and acute toxin-induced injury.